<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139618</url>
  </required_header>
  <id_info>
    <org_study_id>2013-01INT</org_study_id>
    <nct_id>NCT02139618</nct_id>
  </id_info>
  <brief_title>Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage</brief_title>
  <official_title>A Double-blind Randomized-controlled Trial to Assess the Efficacy of Methyl Aminolevulinate + Daylight vs Placebo + Daylight in Patients With Facial Photodamage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Dermabase</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo de Investigacion Dermatologica (GRID)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IPS Universitaria-Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Dermabase</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of actinic damage has included multiple procedures but to date there is limited
      scientific evidence to support the preferential use of one of these therapies according to
      their efficacy, safety and pain tolerance by patients. This study aims to assess the efficacy
      of methyl aminolevulinate + daylight vs placebo + daylight to treat facial photodamage
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global photodamage improvement</measure>
    <time_frame>1 month after third session</time_frame>
    <description>The primary outcome is global photodamage improvement 1 month after the third daylight PDT session, according to Dover´s photodamage scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain measurement</measure>
    <time_frame>After 2 hours of sun exposure in each session</time_frame>
    <description>Pain evaluation with the visual analogue scale after 2 hours of sun exposure in each of the sessions performed (Sessions 1, 2 and 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Photodamage score</measure>
    <time_frame>1 month after the third session</time_frame>
    <description>Specific photodamage severity score for fine lines, coarse lines, tactile roughness, mottled pigmentation, sallowness, and erythema one month after the third daylight PDT session, according to Dover´s photodamage scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sun irradiance and illuminance quantification</measure>
    <time_frame>During the 2 hours of each session</time_frame>
    <description>Sun irradiation and illuminance quantification during exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From recruitment until 1 month after the third session</time_frame>
    <description>Any adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy tolerance</measure>
    <time_frame>1 week after sessions 1,2 and 3</time_frame>
    <description>Therapy tolerance will be recorded with a scale that includes a 4-grade severity score for oozing, erythema, oedema, desquamation, pigmentation, and vesiculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment (Skindex-29 Instrument)</measure>
    <time_frame>Basal and 1 month after the third session</time_frame>
    <description>Quality of life assessment (Skindex-29 Instrument)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Facial Photodamage</condition>
  <arm_group>
    <arm_group_label>Methyl Aminolevulinate (MAL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl Aminolevulinate (MAL)</intervention_name>
    <arm_group_label>Methyl Aminolevulinate (MAL)</arm_group_label>
    <other_name>Metvix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with symmetric facial photodamage grade 2 or 3 (Dover´s scale)

          -  Patients willing to participate

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnant or nursing females

          -  Subjects with any photosensitizing disorder

          -  Any active infectious skin disorder

          -  History of herpes simplex in the face

          -  Subjects with less than 6 months of any previous rejuvenation interfering treatments

          -  History of systemic isotretinoin in the last year

          -  Subjects requiring concurrent treatment that would interfere with study objectives
             and/or assessments

          -  History of hypersensitivity reactions

          -  Activities with high sun exposure during 48 hours after treatment

          -  Clinical suspicion of any systemic or local malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Sanclemente, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia. Medellin, Colombia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IPS Universitaria</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>01</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized-controlled-trial</keyword>
  <keyword>Methyl-Aminolevulinate</keyword>
  <keyword>Daylight</keyword>
  <keyword>Photodynamic-therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

